Sermorelin vs MK-677
Head-to-head comparison of Sermorelin and MK-677 for research applications. Both peptides are studied for Anti-Aging and Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Sermorelin | Mk 677 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. | MK-677 binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus, mimicking the hunger hormone ghrelin. |
| Evidence Rating | C — Phase I–II Clinical Trials | C — Phase I–II Clinical Trials |
| Clinical Status | Previously FDA-approved (Geref, discontinued); now used off-label via compounding | Multiple Phase II trials completed. Not FDA-approved. Investigational. |
| Safety Profile | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) | Common: increased appetite (ghrelin agonism), water retention/mild edema, transient muscle pain; Metabolic: may elevate fasting blood glucose and reduce insulin sensitivity (dose-dependent); important for diabetics and pre-diabetics |
| Route | Subcutaneous | Oral (capsule or liquid) |
| Dose Range | 100–300 mcg/day SC | 10–25 mg/day orally |
| Frequency | Once daily (typically before bed) | Once daily |
| Molecular Weight | ~3357.9 g/mol | ~528.7 g/mol (624.8 as mesylate salt) |
| Half-Life | ~10–20 minutes | ~4–6 hours (plasma); functional activity ~24 hours |
Overview
Sermorelin and MK-677 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
MK-677 — Mechanism & Evidence
MK-677 (Ibutamoren) is a potent, long-acting, orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release without injections. Unlike injectable GH peptides such as GHRP-6 or Ipamorelin, MK-677 can be taken orally and maintains elevated GH and IGF-1 levels for up to 24 hours. It has been studied in several human clinical trials for GH deficiency, muscle wasting, bone density, and sleep quality, but is not FDA-approved for any indication.
Key claims: Increases growth hormone and IGF-1 levels; Improves sleep quality; Increases lean body mass.
Shared Research Applications
Both peptides are studied for: Anti-Aging, Body Composition, Sleep.
Sermorelin is also researched for: no additional unique applications.
MK-677 is also researched for: no additional unique applications.
Safety Considerations
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
MK-677: Common: increased appetite (ghrelin agonism), water retention/mild edema, transient muscle pain Metabolic: may elevate fasting blood glucose and reduce insulin sensitivity (dose-dependent); important for diabetics and pre-diabetics Fatigue and lethargy reported by some users
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
CJC-1295 vs Sermorelin: Comparing Growth Hormone-Releasing Peptides
Compare CJC-1295 vs Sermorelin for growth hormone release. Analyze mechanisms, preclinical data, and research limitations for these GHRH analogs.
Tesamorelin vs Sermorelin: Comparing GHRH Analogues in Research
Compare tesamorelin vs sermorelin GHRH analogues for research. Explore mechanisms, preclinical findings, and evidence limitations.
Sermorelin Effects on Pituitary and Testicular Cells
Sermorelin, a 29-amino-acid analog of growth hormone-releasing hormone, activates receptors on anterior pituitary cells to boost hGH secretion roughly twofold, from 1.1 to 2.2 μg/L over 12 hours. Studies show this leads to IGF-1 increases of 27-28% and may enhance testosterone production in Leydig cells via upregulated IGF-1. Lab experiments highlight cAMP-PKA signaling and calcium-dependent mechanisms driving these responses.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe